Company intelligence / Profile preview

52North

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

52North has developed Neutrocheck®, a point-of-care diagnostic device and app to monitor chemotherapy patients at home for neutropenic sepsis risk. The company has raised significant funding to bring this product to market, expand its pipeline, and develop AI-driven remote monitoring platforms. Clinical results are not yet published but the technology aims to reduce unnecessary hospital visits and improve patient safety.

Therapeutic areas: Oncology
Modalities: DeviceDigital health platform
Industry: Physiological Monitoring

Drug pipeline

1 asset

Neutrocheck

Pre-clinical

Indications: Neutropenia, Neutropenic sepsis

Partnerships

KHP Ventures (King’s Health Partners)Cedars-Sinai Intellectual Property Co.Cancer Research HorizonsMacmillan Cancer SupportCambridge Enterprise Ventures

Beyond the preview

Go deeper on 52North.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 52North.

Explore the full profile